Guizhou Sanli Pharmaceutical Co.,Ltd (SHA:603439)
China · Delayed Price · Currency is CNY 11.25
+0.07 (0.63%)
Apr 30, 2026, 3:00 PM CST
SHA:603439 Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Net Income | 50.62 | 48.15 | 274.03 | 292.7 | 201.28 | 152.28 |
Depreciation & Amortization | 74.06 | 74.06 | 74.86 | 36.9 | 16.19 | 11.17 |
Other Amortization | 0.32 | 0.32 | 1.15 | 0.69 | 1.66 | 0.04 |
Loss (Gain) From Sale of Assets | 0.12 | 0.12 | 0.17 | -0.59 | 0.09 | 0.15 |
Asset Writedown & Restructuring Costs | 129.7 | 129.7 | 0.57 | 0.05 | 0.18 | 0.01 |
Loss (Gain) From Sale of Investments | 2.77 | 2.77 | -1.96 | -55.16 | -10.96 | -17.87 |
Provision & Write-off of Bad Debts | - | - | 9.9 | 3.35 | 10.3 | 0.99 |
Other Operating Activities | 45.89 | 19.68 | 31.51 | 10.89 | -3.95 | 4.79 |
Change in Accounts Receivable | 196.23 | 196.23 | -295.56 | -124.07 | -79.55 | -83.04 |
Change in Inventory | 92.68 | 92.68 | -147.99 | -7.06 | -9.45 | -41.13 |
Change in Accounts Payable | -408.69 | -408.69 | 167.69 | 119.02 | 161.24 | 127.24 |
Change in Other Net Operating Assets | 13.73 | 13.73 | 0.15 | 4.14 | 6.3 | 0.76 |
Operating Cash Flow | 193.25 | 164.58 | 107.07 | 276.7 | 293.29 | 155.04 |
Operating Cash Flow Growth | 125.02% | 53.71% | -61.30% | -5.66% | 89.17% | 145.13% |
Capital Expenditures | -25.89 | -25.84 | -45.2 | -108.73 | -119.91 | -26.08 |
Sale of Property, Plant & Equipment | 0.07 | 0.64 | 0.55 | 2.05 | 0.18 | 0.05 |
Cash Acquisitions | - | - | - | -543.04 | -160.04 | - |
Divestitures | - | - | - | -0.01 | 0.65 | - |
Investment in Securities | -34 | -206.83 | -59.96 | 34.5 | 38 | 80.7 |
Other Investing Activities | -119.76 | 3.59 | 1.61 | 1.45 | 1.92 | -34.08 |
Investing Cash Flow | -179.59 | -228.44 | -103 | -613.78 | -266.56 | 20.59 |
Short-Term Debt Issued | - | - | - | - | - | 200 |
Long-Term Debt Issued | - | 570.54 | 351.22 | 504 | 205 | - |
Total Debt Issued | 518.53 | 570.54 | 351.22 | 504 | 205 | 200 |
Short-Term Debt Repaid | - | - | - | - | - | -200 |
Long-Term Debt Repaid | - | -418.91 | -309.7 | -205.45 | -200 | - |
Total Debt Repaid | -523.11 | -418.91 | -309.7 | -205.45 | -200 | -200 |
Net Debt Issued (Repaid) | -4.58 | 151.64 | 41.52 | 298.55 | 5 | - |
Issuance of Common Stock | - | - | 39.23 | - | - | 26.55 |
Repurchase of Common Stock | - | - | -100.41 | -30 | - | - |
Common Dividends Paid | -160.64 | -161.44 | -104.04 | -50.92 | -8.92 | -110.21 |
Dividends Paid | -160.64 | -161.44 | -104.04 | -50.92 | -8.92 | -110.21 |
Other Financing Activities | -11.99 | -11.76 | 23.12 | 120 | 3.8 | 2.2 |
Financing Cash Flow | -177.22 | -21.57 | -100.6 | 337.63 | -0.12 | -81.46 |
Net Cash Flow | -163.55 | -85.43 | -96.53 | 0.55 | 26.6 | 94.17 |
Free Cash Flow | 167.36 | 138.74 | 61.87 | 167.97 | 173.38 | 128.96 |
Free Cash Flow Growth | 269.53% | 124.23% | -63.16% | -3.12% | 34.45% | 1017.56% |
Free Cash Flow Margin | 9.99% | 8.15% | 2.89% | 10.27% | 14.43% | 13.73% |
Free Cash Flow Per Share | 0.40 | 0.33 | 0.15 | 0.41 | 0.42 | 0.31 |
Cash Income Tax Paid | 185.89 | 191.18 | 210.8 | 175.31 | 116.04 | 100.28 |
Levered Free Cash Flow | 147.79 | -57.24 | 97.65 | -36.78 | 127.68 | 54.78 |
Unlevered Free Cash Flow | 147.83 | -57.24 | 106.78 | -34.2 | 130.96 | 59.99 |
Change in Working Capital | -110.22 | -110.22 | -283.17 | -12.13 | 78.49 | 3.47 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.